Chukwuemeka Ihemelandu1, Chaoyi Zheng2, Erin Hall3, Russell C Langan2, Nawar Shara4, Lynt Johnson5, Waddah Al-Refaie6. 1. Department of General Surgery, MedStar Washington Hospital Center, 106 Irving St, NW, POB Suite 3900, Washington, DC, 20010, USA. Electronic address: Chukwuemeka.u.Ihemelandu@medstar.net. 2. MedStar-Georgetown Surgical Outcomes Research Center, Washington, DC, USA. 3. Department of Surgery, MedStar-Georgetown University Hospital, Washington, DC, USA. 4. MedStar-Georgetown Surgical Outcomes Research Center, Washington, DC, USA; MedStar Health Research Institute, Hyattsville, Maryland, USA. 5. MedStar-Georgetown Surgical Outcomes Research Center, Washington, DC, USA; Department of Surgery, MedStar-Georgetown University Hospital, Washington, DC, USA; Lombardi Comprehensive Cancer Center, Washington, DC, USA. 6. MedStar-Georgetown Surgical Outcomes Research Center, Washington, DC, USA; MedStar Health Research Institute, Hyattsville, Maryland, USA; Lombardi Comprehensive Cancer Center, Washington, DC, USA.
Abstract
BACKGROUND: The Institute of Medicine has recently prioritized access of quality cancer care to vulnerable persons including multimorbid patients. Despite promotional efforts to regionalize major surgical procedures to high-volume hospitals (HVHs), little is known about change in access to HVH over time among multimorbid patients in need of major cancer surgery. We performed a time-trend appraisal of access of multimorbid persons to HVH for major cancer surgery within a large nationally representative cohort. METHODS: We identified 168,934 patients who underwent 6 major cancer surgeries from the Nationwide Inpatient Sample (1998 to 2010). Comorbidities were identified using Elixhauser's method. HVHs were defined as hospitals of highest procedure volumes that treated 1/3 of all the patients. Logistic regression models and predictive margins were used to assess the adjusted effects of comorbidity on receiving major cancer surgeries at HVH. RESULTS: Of all, 45.7% of the patients had 2 comorbidities or more. Multimorbidity predicted decreased access to HVH for esophagectomy, total gastrectomy, pancreatectomy, hepatectomy, and proctectomy, but not for distal gastrectomy, after controlling for covariates. A comorbidity level by year interaction analysis also showed that little disparity existed for receiving distal gastrectomy at an HVH, whereas the predicted difference in probability of receiving any of the other 5 major cancer procedures remained prominent between the years 1998 and 2010. CONCLUSIONS: In this large 12-year time-trend study, multimorbid cancer patients have sustained low access to HVH for major cancer surgery across many oncologic resections. These results continue to reinforce and highlight the need for policy targeted research and intervention aimed at improving these access gaps.
BACKGROUND: The Institute of Medicine has recently prioritized access of quality cancer care to vulnerable persons including multimorbid patients. Despite promotional efforts to regionalize major surgical procedures to high-volume hospitals (HVHs), little is known about change in access to HVH over time among multimorbid patients in need of major cancer surgery. We performed a time-trend appraisal of access of multimorbid persons to HVH for major cancer surgery within a large nationally representative cohort. METHODS: We identified 168,934 patients who underwent 6 major cancer surgeries from the Nationwide Inpatient Sample (1998 to 2010). Comorbidities were identified using Elixhauser's method. HVHs were defined as hospitals of highest procedure volumes that treated 1/3 of all the patients. Logistic regression models and predictive margins were used to assess the adjusted effects of comorbidity on receiving major cancer surgeries at HVH. RESULTS: Of all, 45.7% of the patients had 2 comorbidities or more. Multimorbidity predicted decreased access to HVH for esophagectomy, total gastrectomy, pancreatectomy, hepatectomy, and proctectomy, but not for distal gastrectomy, after controlling for covariates. A comorbidity level by year interaction analysis also showed that little disparity existed for receiving distal gastrectomy at an HVH, whereas the predicted difference in probability of receiving any of the other 5 major cancer procedures remained prominent between the years 1998 and 2010. CONCLUSIONS: In this large 12-year time-trend study, multimorbid cancerpatients have sustained low access to HVH for major cancer surgery across many oncologic resections. These results continue to reinforce and highlight the need for policy targeted research and intervention aimed at improving these access gaps.
Authors: John D Birkmeyer; Andrea E Siewers; Emily V A Finlayson; Therese A Stukel; F Lee Lucas; Ida Batista; H Gilbert Welch; David E Wennberg Journal: N Engl J Med Date: 2002-04-11 Impact factor: 91.245
Authors: Emily V A Finlayson; John D Birkmeyer; Therese A Stukel; Andrea E Siewers; F Lee Lucas; David E Wennberg Journal: Surgery Date: 2002-11 Impact factor: 3.982
Authors: Eva J A Morris; Elizabeth F Taylor; James D Thomas; Philip Quirke; Paul J Finan; Michel P Coleman; Bernard Rachet; David Forman Journal: Gut Date: 2011-04-12 Impact factor: 23.059
Authors: Quoc-Dien Trinh; Maxine Sun; Jesse Sammon; Marco Bianchi; Shyam Sukumar; Khurshid R Ghani; Wooju Jeong; Ali Dabaja; Shahrokh F Shariat; Paul Perrotte; Piyush K Agarwal; Craig G Rogers; James O Peabody; Mani Menon; Pierre I Karakiewicz Journal: Cancer Date: 2012-02-01 Impact factor: 6.860
Authors: Gregory D Kennedy; Victoria Rajamanickam; Erin S O'connor; Noelle K Loconte; Eugene F Foley; Glen Leverson; Charles P Heise Journal: Ann Surg Date: 2011-03 Impact factor: 12.969
Authors: David C Chang; Yiyi Zhang; Debraj Mukherjee; Christopher L Wolfgang; Richard D Schulick; John L Cameron; Nita Ahuja Journal: J Am Coll Surg Date: 2009-12 Impact factor: 6.113
Authors: Manila Jindal; Chaoyi Zheng; Humair S Quadri; Chukwuemeka U Ihemelandu; Young K Hong; Andrew K Smith; Vikas Dudeja; Nawar M Shara; Lynt B Johnson; Waddah B Al-Refaie Journal: J Am Coll Surg Date: 2017-04-14 Impact factor: 6.113